MedTrace Logo

The Effects of Ceylon Cinnamon (Cinnamomum Verum) Supplementation on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Intensity Among Adult Individuals With Painful Diabetic Peripheral Neuropathy

NCT07743073 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2026-08-03

No results posted yet for this study

Summary

Background: Painful diabetic peripheral neuropathy (PDPN) is a severe, disabling complication of type 2 diabetes mellitus (T2DM), closely associated with insulin resistance, chronic neuroinflammation, and oxidative stress. Plant-based dietary supplements, particularly Ceylon cinnamon (Cinnamomum verum), contain bioactive compounds with potential anti-diabetic, antioxidant, and neuroprotective properties.

Aim: To evaluate the effects of Ceylon Cinnamon (Cinnamomum verum) supplementation on blood glucose, lipid profile levels, body mass index (BMI), and pain intensity among adult individuals with painful diabetic peripheral neuropathy (PDPN).

Methods: A prospective, double-blind, randomized controlled trial (Double-Blind RCT) was conducted (Feb-July 2026) across endocrinology outpatient clinics in Jordan. Participants were randomly allocated in a 1:1 ratio to either the Intervention Group (n = 62; 500 mg Ceylon cinnamon twice daily for 6 months alongside standard care) or the Placebo Control Group (n = 62; 500 mg placebo capsules twice daily for 6 months alongside standard care). Clinical, biochemical, and pain assessments (using the Numeric Rating Scale \[NRS\]) were evaluated at baseline, 3 months, and 6 months post-intervention.

Conditions

  • Painful Diabetic Peripheral Neuropathy

Interventions

DIETARY_SUPPLEMENT

Ceylon Cinnamon Supplement

500 mg Ceylon cinnamon twice daily for 6 months

Sponsors & Collaborators

  • JAWAD AHMAD ABU-SHENNAR

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2026-05-30
Completion
2026-07-30

Countries

  • Jordan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07743073 on ClinicalTrials.gov